B
Brian J. P. Huntly
Researcher at University of Cambridge
Publications - 168
Citations - 21295
Brian J. P. Huntly is an academic researcher from University of Cambridge. The author has contributed to research in topics: Myeloid leukemia & Leukemia. The author has an hindex of 54, co-authored 144 publications receiving 19135 citations. Previous affiliations of Brian J. P. Huntly include Cambridge University Hospitals NHS Foundation Trust & Brigham and Women's Hospital.
Papers
More filters
Journal ArticleDOI
Glutaminolysis is a metabolic dependency in FLT3ITD acute myeloid leukemia unmasked by FLT3 tyrosine kinase inhibition
Paolo Gallipoli,Paolo Gallipoli,George Giotopoulos,George Giotopoulos,Konstantinos Tzelepis,Ana S. H. Costa,Shabana Vohra,Shabana Vohra,Paula Medina-Perez,Faisal Basheer,Faisal Basheer,Ludovica Marando,Ludovica Marando,Lorena Di Lisio,Lorena Di Lisio,João Lopes Dias,João Lopes Dias,Haiyang Yun,Haiyang Yun,Daniel Sasca,Daniel Sasca,Sarah J. Horton,Sarah J. Horton,George S. Vassiliou,George S. Vassiliou,Christian Frezza,Brian J. P. Huntly,Brian J. P. Huntly +27 more
TL;DR: This work highlights the role of metabolic adaptations as a resistance mechanism to several TKI and suggests glutaminolysis as a therapeutically targetable vulnerability when combined with specific TKI in FLT3ITD and other TK activating mutation-driven leukemias.
Journal ArticleDOI
The EOL-1 cell line as an in vitro model for the study of FIP1L1-PDGFRA–positive chronic eosinophilic leukemia
Jan Cools,Hilmar Quentmeier,Brian J. P. Huntly,Peter Marynen,James D. Griffin,Hans G. Drexler,D. Gary Gilliland +6 more
TL;DR: EOL-1 is identified as an in vitro model for the study of FIP1L1-PDGFRA-positive chronic eosinophilic leukemia and for the analysis of small molecule inhibitors of Fip1L 1-PDGFRalpha.
Journal ArticleDOI
Clinical utility of routine MPL exon 10 analysis in the diagnosis of essential thrombocythaemia and primary myelofibrosis
Elaine M. Boyd,Anthony J. Bench,Andrea Goday-Fernandez,Shubha Anand,Krishna J. Vaghela,Phillip Beer,Michael A. Scott,David Bareford,Anthony R. Green,Brian J. P. Huntly,Wendy N. Erber +10 more
TL;DR: A high resolution melt assay is developed and applied, capable of detecting all known MPL mutations in a single analysis, for the detection of MPL exon 10 mutations, which increases the sensitivity of meeting the World Health Organization diagnostic criteria for these myeloproliferative neoplasms.
Journal ArticleDOI
Bone Marrow Mesenchymal Stem Cells Support Acute Myeloid Leukemia Bioenergetics and Enhance Antioxidant Defense and Escape from Chemotherapy
Dorian Forte,Dorian Forte,María García-Fernández,Abel Sanchez-Aguilera,Vaia Stavropoulou,Claire Fielding,Daniel Martín-Pérez,Juan Antonio López,Ana S. H. Costa,Laura Tronci,Efterpi Nikitopoulou,Michael Barber,Paolo Gallipoli,Ludovica Marando,Carlos Lopez Fernandez de Castillejo,Alexandar Tzankov,Sabine Dietmann,Michele Cavo,Lucia Catani,Antonio Curti,Jesús Vázquez,Christian Frezza,Brian J. P. Huntly,Juerg Schwaller,Simón Méndez-Ferrer +24 more
TL;DR: Nestin+ BMSCs support survival and chemotherapy relapse of AML through increased oxidative phosphorylation, tricarboxylic acid (TCA) cycle activity, and glutathione (GSH)-mediated antioxidant defense, therefore, AML cells co-opt energy sources and antioxidant defense mechanisms from B MSCs to survive chemotherapy.
Journal ArticleDOI
Clonal diversity in the myeloproliferative neoplasms: independent origins of genetically distinct clones.
Philip A. Beer,Amy V. Jones,Anthony J. Bench,Andrea Goday-Fernandez,Elaine M. Boyd,Krishna J. Vaghela,Wendy N. Erber,Bassam Odeh,Christine Wright,Mary Frances McMullin,Jonathan O. Cullis,Brian J. P. Huntly,Claire N. Harrison,Nicholas C.P. Cross,Anthony R. Green +14 more
TL;DR: Clonal diversity was demonstrated in a subset of patients with early stage haematopoietic malignancy and it was shown, for the first time, that such clones may arise independently.